Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Handheld scanners and glucose monitors aim to catch diseases early

NCT ID NCT07209527

Diagnosis Sponsor: Truway Health, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether portable ultrasound and blood glucose monitors can help doctors catch chronic conditions like diabetes, heart disease, and kidney disease earlier than usual. About 200 adults will use these devices or receive standard care for 6 months. The goal is to see if the devices improve detection rates and patient outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Truway Portable Ultrasound Device and Truway Blood Glucose Monitor
What this could lead to
If successful, this could make early detection of chronic diseases easier and more accessible in primary care, potentially improving outcomes.
What could go wrong
This is an early-phase study with only 200 participants, so results may not apply broadly. The devices may not significantly improve detection over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age 18 to 75 years, inclusive Ability to understand the study procedures and provide written informed consent Diagnosis of the target condition according to established clinical or diagnostic criteria Stable treatment regimen (pharmacologic or non-pharmacologic) for at least 4 weeks prior to screening Willingness and ability to comply with all study visits, procedures, and follow-up assessments - Exclusion Criteria: Pregnancy or breastfeeding at the time of enrollment Known hypersensitivity to any components of the investigational intervention Uncontrolled or unstable comorbid conditions (for example, cardiovascular, hepatic, renal, or psychiatric disorders) Participation in another interventional clinical trial within the past 3 months Cognitive impairment or language barrier that would preclude valid informed consent or reliable reporting \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome cardiovascular disorder Chronic Disease chronic kidney disease chronic renal failure syndrome diabetes mellitus hyperlipidemia hypertensive disorder metabolic syndrome X Obesity obesity disorder Overweight peripheral arterial disease prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease acute Chronic disease Chronic kidney disease (CKD), stages 3-4 exercise tolerance / functional capacity vascular health / arterial stiffness fatigue in CKD Hyperlipidemia Hypertension Metabolic syndrome Peripheral artery disease Prediabetes Type 2 diabetes mellitus (T2DM), obesity, overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Truway Health, Inc.

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.